ATE262530T1 - Indolochinazolinone - Google Patents

Indolochinazolinone

Info

Publication number
ATE262530T1
ATE262530T1 AT01957972T AT01957972T ATE262530T1 AT E262530 T1 ATE262530 T1 AT E262530T1 AT 01957972 T AT01957972 T AT 01957972T AT 01957972 T AT01957972 T AT 01957972T AT E262530 T1 ATE262530 T1 AT E262530T1
Authority
AT
Austria
Prior art keywords
indolochinazolinone
Prior art date
Application number
AT01957972T
Other languages
German (de)
English (en)
Inventor
Kaspar Zimmermann
Robert Portmann
Dean Franklin Rigel
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE262530T1 publication Critical patent/ATE262530T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AT01957972T 2000-07-17 2001-07-16 Indolochinazolinone ATE262530T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0017508.3A GB0017508D0 (en) 2000-07-17 2000-07-17 Antimicrobials
PCT/EP2001/008192 WO2002006284A1 (en) 2000-07-17 2001-07-16 Indoloquinazolinones

Publications (1)

Publication Number Publication Date
ATE262530T1 true ATE262530T1 (de) 2004-04-15

Family

ID=9895801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957972T ATE262530T1 (de) 2000-07-17 2001-07-16 Indolochinazolinone

Country Status (18)

Country Link
US (1) US6964960B2 (cg-RX-API-DMAC7.html)
EP (1) EP1303517B1 (cg-RX-API-DMAC7.html)
JP (1) JP3939246B2 (cg-RX-API-DMAC7.html)
CN (1) CN1183136C (cg-RX-API-DMAC7.html)
AR (1) AR031379A1 (cg-RX-API-DMAC7.html)
AT (1) ATE262530T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001279754A1 (cg-RX-API-DMAC7.html)
BR (1) BR0112521A (cg-RX-API-DMAC7.html)
CA (1) CA2415683C (cg-RX-API-DMAC7.html)
DE (1) DE60102473T2 (cg-RX-API-DMAC7.html)
DK (1) DK1303517T3 (cg-RX-API-DMAC7.html)
ES (1) ES2218439T3 (cg-RX-API-DMAC7.html)
GB (1) GB0017508D0 (cg-RX-API-DMAC7.html)
MY (1) MY133969A (cg-RX-API-DMAC7.html)
PE (1) PE20020210A1 (cg-RX-API-DMAC7.html)
PT (1) PT1303517E (cg-RX-API-DMAC7.html)
TR (1) TR200401026T4 (cg-RX-API-DMAC7.html)
WO (1) WO2002006284A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
EP1855676A4 (en) 2005-02-25 2008-05-21 Inotek Pharmaceuticals Corp TETRAZYCLIC AMINO AND CARBOXAMIDE COMPOUNDS AND METHOD FOR THEIR USE
US7652028B2 (en) 2005-08-24 2010-01-26 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
WO2007149907A2 (en) * 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
KR20090115879A (ko) 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
EP2157972A1 (en) 2007-05-08 2010-03-03 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
WO2013008872A1 (ja) * 2011-07-13 2013-01-17 参天製薬株式会社 Ｐａｒｐ阻害活性を有する新規化合物
CN102766144B (zh) * 2012-07-10 2014-04-23 浙江大学 一种吲哚并[1,2-c]喹唑啉化合物的制备方法
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2019235337A1 (en) 2018-03-13 2020-08-27 Centre National De La Recherche Scientifique A Dbait molecule against acquired resistance in the treatment of cancer
US20220073531A1 (en) * 2018-11-30 2022-03-10 Merck Patent Gmbh Compounds for electronic devices
US20220162205A1 (en) * 2019-03-12 2022-05-26 Merck Patent Gmbh Materials for organic electroluminescent devices
CN110357892B (zh) * 2019-07-10 2022-06-07 云南大学 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114195789B (zh) * 2021-12-15 2022-09-09 广东海洋大学 一种无金属参与的多环吲哚衍生物的制备方法
AU2024312126A1 (en) 2023-06-21 2025-12-11 Tetragon Biosciences Ltd. Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635966A (en) 1969-10-22 1972-01-18 Robins Co Inc A H 6-substituted-indolo(1 2-c)quinazolines
DE2237372C3 (de) 1972-07-29 1981-07-09 Basf Ag, 6700 Ludwigshafen Heterocyclische Farbstoffe, ihre Herstellung und ihre Verwendung
US5441955A (en) * 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
MY133969A (en) 2007-11-30
CN1441803A (zh) 2003-09-10
CA2415683A1 (en) 2002-01-24
WO2002006284A1 (en) 2002-01-24
CN1183136C (zh) 2005-01-05
AU2001279754A1 (en) 2002-01-30
ES2218439T3 (es) 2004-11-16
US6964960B2 (en) 2005-11-15
PE20020210A1 (es) 2002-04-04
HK1055426A1 (en) 2004-01-09
EP1303517A1 (en) 2003-04-23
EP1303517B1 (en) 2004-03-24
DE60102473D1 (de) 2004-04-29
BR0112521A (pt) 2003-07-01
AR031379A1 (es) 2003-09-24
PT1303517E (pt) 2004-07-30
GB0017508D0 (en) 2000-08-30
JP3939246B2 (ja) 2007-07-04
DE60102473T2 (de) 2005-02-03
DK1303517T3 (da) 2004-06-21
US20030199502A1 (en) 2003-10-23
TR200401026T4 (tr) 2004-07-21
JP2004504323A (ja) 2004-02-12
HK1056872A1 (en) 2004-03-05
CA2415683C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE50106867D1 (de) Kugelgelenk
DE50102988D1 (de) Bodenwischer
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
DE60102473D1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
DE50104651D1 (de) Fahrzeugfaltverdeck
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
AR027931A1 (es) Antitranspirantes
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE50007634D1 (de) Kardioplegieballonkatheter
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone
DE50103443D1 (de) Doppelwandbohrrohr

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1303517

Country of ref document: EP

REN Ceased due to non-payment of the annual fee